Fig. 7
From: Advancements in nanoparticle-based treatment approaches for skin cancer therapy
Schematic illustration of the design and therapeutic strategy of SHP. Part I: Synthesis of PAE and preparation of SHP micelle from the PAE, HA and SCP. Part II: Topical application of SHP/SiRNA induces survivin slicing in skin melanoma. (1) SHP/SiRNA nanocomplexes penetrate through the skin stratum corneum and target to melanoma locates at the interface of epidermis and dermis. (2) SHP/SiRNA-survivin nanocomplexes are uptaken by melanoma cells. (3) SHP/SiRNAsurvivin nanocomplexes escaped from the lysosome, release the siRNA that bind to the targeting RNA, followed by slicing survivin, which possesses the great potential to induce the significant apoptosis to melanoma cells in vitro and retard the melanoma progression in vivo, reproduced with permission from [249], copyright 2020, Elsevier